An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas

Molecular Therapy

Volumn 15, Issue 6, 2007, Pages 1129-1136

  Lam, Paula Y P ^a   Sia, Kian Chuan ^a   Khong, Jenn H ^b   De Geest, Bart ^c   Lim, Kar S ^d   Ho, Ivy A W ^a   Wang, Grace Y ^a   Miao, Lv ^a   Huynh, H ^a   Hui, Kam M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN E; HYBRID PROTEIN; NUCLEAR FACTOR Y; TRANSCRIPTION FACTOR GAL4; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOLUMINESCENCE; CELL PROLIFERATION; CONTROLLED STUDY; ENHANCER REGION; FEMALE; GENE EXPRESSION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PROMOTER REGION; SCID MOUSE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY;

ALPHA 1-ANTITRYPSIN; ALPHA-FETOPROTEINS; ANIMALS; APOLIPOPROTEINS E; CARCINOMA, HEPATOCELLULAR; CCAAT-BINDING FACTOR; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOBLOTTING; LIVER NEOPLASMS; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, SCID; MICROSCOPY, FLUORESCENCE; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 1;

EID: 34249677913     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300165     Document Type: Article

References (40)

1. Liu, N, Lucibello, FC, Korner, K, Wolfraim, LA, Zwicker, J and Muller, R (1997). CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res 25: 4915-4920.
2. Zwicker, J, Lucibello, FC, Wolfraim, LA, Gross, C, Truss, M, Engeland, K et al. (1995). Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J 14: 4514-4522.
3. Nettelbeck, DM, Jerome, V and Muller, R (1999). A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther 6: 1276-1281.
4. Tung, C, Federoff, HJ, Brownlee, M, Karpoff, H, Weigel, T, Brennan, MF et al. (1996). Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production. Hum Gene Ther 7: 2217-2224.
5. Jamagin, WR, Delman, K, Kooby, D, Mastorides, S, Zager, J, Brennan, MF et al. (2000). Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 231: 762-771.
6. Delman, KA, Zager, JS, Bennett, JJ, Malhotra, S, Ebright, MI, McAuliffe, PF et al. (2002). Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg 236: 337-342; discussion 342-333.
7. Fraefel, C, Jacoby, DR, Lage, C, Hilderbrand, H, Chou, JY, Alt, FW et al. (1997). Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 3: 813-825.
8. Muller, L, Saydam, O, Saeki, Y, Heid, I and Fraefel, C (2005). Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol Methods 123: 65-72.
9. Ho, IA Hui, KM and Lam PY (2004). Glioma-specific and cell cycle-regulated herpes simplex vinis type 1 amplicon viral vector. Hum Gene Ther 15: 495-508.
10. Ho, IA, Hui, KM and Lam, PY (2006). Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther 13: 44-52.
11. Rampling, R, Cruickshank, G, Papanastassiou, V, Nicoll, J, Hadley, D, Brennan, D et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866.
12. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867-874.
13. Huynh, H, Soo, KC, Chow, PK, Panasci, L and Tran, E (2006). Xenografts of human hepatocellular carcinoma: A useful model for testing drugs. Clin Cancer Res 12: 4306-4314.
14. Coleman, WB (2003). Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588.
15. Cao, G, Kuriyama, S, Tsujinoue, H, Chen, Q, Mitoro, A and Qi, Z (2000). A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. Int J Cancer 87 247-252.
16. Nettelbeck, DM, Jerome, V and Muller, R (2000). Gene therapy: Designer promoters for tumour targeting. Trends Genet 16: 174-181.
17. Papadakis, ED, Nicklin, SA, Baker, AH and White, SJ (2004). Promoters and control elements: Designing expression cassettes for gene therapy. Curr Gene Ther 4: 89-113.
18. Arbuthnot PB, Bralet, MP, Le Jossic, C, Dedieu, JF, Perricaudet, M, Brechot, C et al. (1996). In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 7: 1503-1514.
19. Mawatari, F, Tsuruta, S, Ido, A, Ueki, T, Nakao, K, Kato, Y et al. (1998). Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther 5: 301-306.
20. Condiotti, R, Curran, MA, Nolan, GP, Giladi, H, Ketzinel-Gilad, M, Gross, E et al. (2004). Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun 320: 998-1006.
21. Gerolami, R, Uch, R, Jordier, F, Chapel, S, Bagnis, C, Brechot, C et al. (2000). Gene transfer to hepatocellular carcinoma: Transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther 7: 1286-1292.
22. Everett, RS, Evans, HK, Hodges, BL, Ding, EY, Serra DM and Amalfitano, A (2004). Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors. Virology 325: 96-105.
23. Van Linthout, S, Collen, D and De Geest B (2002). Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. Hum Gene Ther 13: 829-840.
24. Pin, RH, Reinblatt, M, Bowers, WJ, Federoff, HJ and Fong, Y (2004). Herpes simplex virus amplicon delivery of a hypoxia-inclucible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J Gastrointest Surg 8: 812-822; discussion 822-813.
25. Nakai, H, Storm, TA and Kay, MA (2000). Increasing the size of rAAV-mediated epression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 18: 527-532.
26. Le Bec, C and Douar, AM (2006). Gene therapy progress and prospects-vectorology: Design and production of expression cassettes in AAV vectors. Gene Ther 13: 805-813.
27. Hibbitt OC and Wade-Martins, R (2006). Delivery of large genomic DNA inserts>100 kb using HSV-1 amplicons. Curr Gene Ther 6: 325-336.
28. Wade-Martins, R, Smith, ER, Tyminski, E, Chiocca, EA and Saeki, Y (2001). An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 19: 1067-1070.
29. Senior, SL and Wade-Martins, R (2005). Herpes simplex virus type 1 amplicon vectors for the infectious delivery and expression of genomic DNA loci. Curr Opin Mol Ther 7: 337-345.
30. Miyatake, SI, Tani, S, Feigenbaum, F, Sundaresan, P, Toda, H, Narumi, O et al. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 6: 564-572.
31. Pawlik, TM, Nakamura, H, Yoon, SS, Mullen, JT, Chandrasekhar, S, Chiocca, EA et al. (2000). Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent genetically engineered herpesvirus. Cancer Res 60: 2790-2795.
32. Steer, CJ (1995). Liver regeneration. FASEB J 9: 1396-1400.
33. Michalopoulos, GK and DeFrances, MC (1997). Liver regeneration. Science 276: 60-66.
34. Smith, IL, Hardwicke, MA and Sandri-Goldin, RM (1992). Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 186: 74-86.
35. Pichard, L, Raulet, E, Fabre, G, Ferrini, JB, Ourlin, JC and Maurel, P (2006). Human hepatocyte culture. Methods Mol Biol 320: 283-293.
36. Van Linthout, S, Lusky, M, Collen, D and De Geest, B (2002). Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther 9: 1520-1528.
37. De Geest, B, Van Linthout, S, Lox, M, Collen, D and Holvoet, P (2000). Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: Role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 11: 101-112.
38. Saeki, Y, Fraefel, C, Ichikawa, T, Breakefield, XO and Chiocca, FA (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3: 591-601.
39. Sia, KC, Wang, GY, Ho, IA, Khor, HY, Miao, L, Hui, KM et al. (2007). Optimal purification method for herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration. J Virol Methods 139: 166-174.
40. Higgins, GM and Anderson, RM (1931). Experimental pathology of the liver I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 12: 186-202.